All In Biotech

Drug Trial Radar · NCT04435626

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Finerenone on Morbidity and Mortality in Participants With Heart Failure (NYHA II-IV) and Left Ventricular Ejection Fraction ≥ 40% (LVEF ≥ 40%)

Last checked: Nov 19, 2026Latest source record: Aug 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 6,016 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,016

Actual

Start

Sep 14, 2020

Primary completion

May 15, 2024

Study completion Jun 14, 2024

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jun 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of finerenone compared to placebo (a tablet without active substance) in the reduction of cardiovascular death (generally meaning death due to disease of the heart or blood vessels) and total Heart Failure (HF) events, including HF hospitalization and urgent visits for HF(generally meaning a hospital stay or urgent presentation to a healthcare unit due to worsening symptoms of heart failure) in patients suffering from HF with an ejection fraction greater than or equal to 40%. Researchers will also collect information on how much the heart disease has impact on patient's lives, change of kidney function, and how well finerenone treatment is tolerated. The study plans to enroll 6000 male and female patients of the age of 40 years and above suffering from heart failure with ejection fraction greater than or equal to 40%. Participants will take the study product as oral tablet with a dose between 0 (Placebo) 40 mg once daily. Study duration will be up to 43 months.

Conditions

  • Heart Failure

Interventions

  • Finerenone (BAY94-8862)Drug

    For participants with an eGFR ≤60 mL/min/1.73 m\^2: Starting dose is 10 mg OD and maximum dose 20 mg OD. For participants with an eGFR \>60 mL/min/1.73 m\^2: Starting dose is 20 mg OD and maximum dose 40 mg OD. Finerenone is administered orally as immediate release tablets.

  • PlaceboOther

    Placebo tablets matching BAY94-8862 are administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure EventsTime frame: From randomization up until the end of study, with an average study duration of 32 months
  2. Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure EventsTime frame: From randomization up until the end of study, with an average study duration of 32 months

Locations

661 sites in 37 countries. Site status is shown where the registry gives one.

  • Cardiology, PC

    Birmingham, Alabama

  • Eastern Shore Research Institute, LLC | Fairhope, AL

    Fairhope, Alabama

  • Mobile Heart Specialists - Providence

    Mobile, Alabama

  • University of Arizona Clinical and Translational Sciences Research Center

    Tucson, Arizona

  • Heart Clinic Arkansas

    Little Rock, Arkansas

  • WestSide Medical

    Beverly Hills, California

  • CA Heart and Vein Specialists

    Huntington Beach, California

  • UCI Medical Center - Neurology

    Orange, California

  • Sutter Medical Center - Cardiology

    Sacramento, California

  • NorthBay Clinical Research, LLC | Santa Rosa, CA

    Santa Rosa, California

  • The Lundquist Institute - Gynecology

    Torrance, California

  • Blue Coast Research Center, LLC

    Vista, California

  • Interventional Cardio Medical- DCT Department

    West Hills, California

  • Interventional Cardiology Medical Group | West Hills, CA

    West Hills, California

  • VA Eastern Colorado Health Care System

    Aurora, Colorado

  • Colorado Springs Cardiology - Woodmen Medical Plaza

    Colorado Springs, Colorado

  • South Denver Cardiology Associates, PC

    Littleton, Colorado

  • Cardiovascular & Vein Center of Florida | Bradenton, FL

    Bradenton, Florida

  • Nova Clinical Research - Blake Medical Center

    Bradenton, Florida

  • Cardiology Associates Research Company

    Daytona Beach, Florida

  • North Florida Foundation for Research and Education - Clinical Trial Center

    Gainesville, Florida

  • LifeSpring Research Foundation, LLC

    Miami, Florida

  • Southwest Florida Research | Naples, FL

    Naples, Florida

  • East Coast Institute for Research | St. Augustine, FL

    Saint Augustine, Florida

  • Cardiology Partners Clinical Research Institute | Wellington Office

    Wellington, Florida

  • Centricity Research at Talbotton

    Columbus, Georgia

  • Atlanta Heart Specialists - Tucker

    Tucker, Georgia

  • Advocate Illinois Masonic Medical Center - Cardiology

    Chicago, Illinois

  • Advocate Good Samaritan Hospital - Cardiology

    Downers Grove, Illinois

  • Advocate Condell Medical Center

    Libertyville, Illinois

  • Edward Hospital - Main Campus - Cardiology

    Naperville, Illinois

  • Captain James A. Lovell Federal Health Care Center

    North Chicago, Illinois

  • Carle Health Methodist Hospital - Cardiology

    Peoria, Illinois

  • Midwest Cardiovascular Research and Education Foundation | Elkhart, IN

    Elkhart, Indiana

  • Reid Physicians Associates - Cardiology Department

    Richmond, Indiana

  • Kansas Nephrology Research Institute

    Wichita, Kansas

  • Baptist Health Paducah - Cardiology

    Paducah, Kentucky

  • Cardiovascular Associates Research, LLC

    Covington, Louisiana

  • Heart Clinic of Hammond

    Hammond, Louisiana

  • Louisiana Heart Center - Slidell

    Slidell, Louisiana

Showing 40 of 661 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.